You have 9 free searches left this month | for more free features.

MDX010

Showing 1 - 25 of 196

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma Trial (Nivolumab, Ipilimumab, Surgical Procedure)

Not yet recruiting
  • Pleural Biphasic Mesothelioma
  • Pleural Sarcomatoid Mesothelioma
  • Nivolumab
  • +5 more
  • (no location specified)
Dec 9, 2022

Squamous Cell Carcinoma of the Head and Neck Trial in Portland (Intratumoral Ipilimumab)

Active, not recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Intratumoral Ipilimumab
  • Portland, Oregon
    Portland Providence Medical Center
Jan 8, 2023

Melanoma Trial in Boston (Bevacizumab Plus Ipilimumab Cohort 1, Bevacizumab Plus Ipilimumab Cohort 2, Bevacizumab Plus

Active, not recruiting
  • Melanoma
  • Bevacizumab Plus Ipilimumab Cohort 1
  • +3 more
  • Boston, Massachusetts
  • +2 more
Nov 8, 2021

Gastrointestinal Stromal Tumor Trial in Los Angeles (Ipilimumab, Laboratory Biomarker Analysis, Nivolumab)

Completed
  • Gastrointestinal Stromal Tumor
  • Ipilimumab
  • +2 more
  • Los Angeles, California
    Rachel Andes
Aug 15, 2022

Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 Trial

Recruiting
  • Advanced Clear Cell Renal Cell Carcinoma
  • +3 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Dec 2, 2022

Kidney Medullary Carcinoma, Loss of INI 1 Protein Expression, Stage III Renal Cell Cancer AJCC v8 Trial in Houston (Ipilimumab,

Active, not recruiting
  • Kidney Medullary Carcinoma
  • +3 more
  • Ipilimumab
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Larynx, Lip, Oral Cavity and Pharynx Trial in Philadelphia (Nivolumab, Ipilimumab, Simultaneous-Integrated Boost

Completed
  • Larynx
  • Lip, Oral Cavity and Pharynx
  • Nivolumab
  • +3 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Nov 16, 2022

Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma Trial in Boston (Ipilimumab, Laboratory

Active, not recruiting
  • Metastatic Leiomyosarcoma
  • +2 more
  • Ipilimumab
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2022

Soft Tissue Sarcoma Trial in Stanford (Ipilimumab, Cryoablation, Nivolumab)

Active, not recruiting
  • Soft Tissue Sarcoma
  • Stanford, California
    Stanford Medical Center
Feb 2, 2022

Metastatic Extraskeletal Myxoid Chondrosarcoma, Metastatic Leiomyosarcoma, Metastatic Liposarcoma Trial (procedure, drug,

Not yet recruiting
  • Metastatic Extraskeletal Myxoid Chondrosarcoma
  • +3 more
  • Biopsy
  • +6 more
  • (no location specified)
Apr 25, 2023

Metastatic Malignant Tumor in the Brain, Stage IV NSCLC AJCC v7 Trial in Houston (procedure, biological, other, radiation)

Recruiting
  • Metastatic Malignant Neoplasm in the Brain
  • Stage IV Non-Small Cell Lung Cancer AJCC v7
  • Cognitive Assessment
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 12, 2022

Squamous Cell Carcinoma of the Head and Neck Trial in Pittsburgh (Nivolumab+Relatlimab, Nivolumab+Ipilimumab)

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 13, 2022

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Jun 13, 2023

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Melanoma Trial in Houston

Recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +3 more
  • Ipilimumab
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in

Not yet recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

Pancreatic Cancer Trial run by the (ipilimumab)

Completed
  • Pancreatic Cancer
  • ipilimumab
  • Bethesda, Maryland
  • +1 more
Sep 24, 2021

Renal Cell Carcinoma Trial in Houston (Ipilimumab, Nivolumab, Ciforadenant)

Not yet recruiting
  • Renal Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Recruiting
  • Acute Bilineal Leukemia
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 24, 2023

Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 Trial in Duarte

Recruiting
  • Clear Cell Renal Cell Carcinoma
  • +3 more
  • Biospecimen Collection
  • +6 more
  • Duarte, California
    City of Hope Medical Center
Sep 19, 2023

Melanoma, Unresectable Melanoma Trial in Los Angeles, Boston, New York (Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab)

Not yet recruiting
  • Melanoma
  • Unresectable Melanoma
  • Los Angeles, California
  • +3 more
Aug 4, 2022

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +3 more
  • Ipilimumab
  • Nivolumab
  • Rochester, Minnesota
    Mayo Clinic in Rochester
May 6, 2022

Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma Trial in Duarte (Clostridium

Active, not recruiting
  • Advanced Renal Cell Carcinoma
  • +5 more
  • Clostridium butyricum CBM 588 Probiotic Strain
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Oct 12, 2022

Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Tumor in the Brain Trial in

Recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +6 more
  • Ipilimumab
  • +4 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Dec 12, 2022

Melanoma Trial in Houston (ABI-007, Ipilimumab, Phone Call)

Completed
  • Melanoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 12, 2022

Advanced Malignant Solid Tumor, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +8 more
  • Imatinib Mesylate
  • Ipilimumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 1, 2022